TRANSCEND involved 120 patients and showed a 19.8% placebo-adjusted BMI reduction; Rhythm plans to finalize UK NHS coverage guidance.Read More
Rhythm’s IMCIVREE authorized in UK for obesity after hypothalamic injury
By Stock Titan
MGSN.net
